Reviewing the amendment protocol of the AstraZeneca's fixed dose combination (FDC) Zibotentan plus Dapagliflozin, the Subject ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending Forxiga (dapagliflozin) as an option to treat chronic ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

The “somewhat unexpected” finding is likely related to the profound impact on health status from the procedure itself.

Use of the AstraZeneca Dapagliflozin Patient Identification Resource (DAPA-id) to identify patients in your practice who may benefit from taking dapagliflozin. • Opportunities to improve your practice ...

AstraZeneca is fighting to prevent Glenmark from launching its generic version of dapagliflozin, a medication widely used for managing Type 2 diabetes. The urgency of the appeal stems from concerns ...

In a reversal of fortune, yesterday (9 April) the UK Court of Appeal awarded AstraZeneca (AZ) an interim injunction keeping Glenmark’s dapagliflozin (dapa) off the UK market until the form of ...

refused to grant AstraZeneca (“AZ”) an interim injunction to restrain Glenmark from launching in the U.K. a generic version of its type 2 diabetes treatment, Forxiga® (dapagliflozin ...

Sun Pharma’s current diabetes portfolio comprises of over 40 specialty products with a market share of more than 8%. Photo: Hemant Mishra/Mint Mumbai: Sun Pharmaceutical Industries Ltd on ...

The study was partially funded by AstraZeneca, the manufacturer of dapagliflozin. Renal and Urology News, a trusted source of medical news and feature content for healthcare providers, offers ...

The study was partially funded by AstraZeneca, the manufacturer of dapagliflozin. Abstract/Full Text Editorial ...

Pharma giant AstraZeneca will spend $26.5 million to build a new production line for its diabetes treatment dapagliflozin and metformin hydrochloride at the Taizhou National Medical High-tech ...